LinkedIn·Wednesday, 12 August 2026·14d ago

📚 𝗜𝗗𝗬𝗟𝗟𝗔™ 𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗛𝗜𝗚𝗛𝗟𝗜𝗚𝗛𝗧𝗦 𝗛𝟭 𝟮𝟬𝟮𝟲 The first half of 2026 brought continued growth in peer-reviewed…

Biocartis

48,291 followers

📚 𝗜𝗗𝗬𝗟𝗟𝗔™ 𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗛𝗜𝗚𝗛𝗟𝗜𝗚𝗛𝗧𝗦 𝗛𝟭 𝟮𝟬𝟮𝟲 The first half of 2026 brought continued growth in peer-reviewed publications supporting the performance, versatility, and clinical relevance of the Idylla™ Platform. 💡 Key takeaways from the H1 2026 Idylla™ publications include: • 𝟭𝟳 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 across 10 products and 11 disease areas • Growing use of Idylla™ in 𝗰𝘆𝘁𝗼𝗹𝗼𝗴𝘆-based molecular testing • Validation of the Idylla™ GeneFusion Assay* in one of the 𝗹𝗮𝗿𝗴𝗲𝘀𝘁 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗡𝗧𝗥𝗞-𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗰𝗼𝗵𝗼𝗿𝘁𝘀 • First published data for the Idylla™ 𝗣𝗢𝗟𝗘-𝗣𝗢𝗟𝗗𝟭 Mutation Assay* • New Idylla™ PIK3CA-AKT1 Mutation Assay* data presented at 𝗘𝗦𝗠𝗢 𝗕𝗿𝗲𝗮𝘀𝘁 𝟮𝟬𝟮𝟲 These publications further expand the scientific evidence supporting the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺, highlighting its continued evolution as a rapid, automated molecular testing solution across a broad range of oncology applications. Over the coming weeks, we will highlight three publications from H1 2026 that showcase how Idylla™ is being evaluated across diverse tumor types, biomarkers, and sample types. Stay tuned! 👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗛𝟭 𝟮𝟬𝟮𝟲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺: https://lnkd.in/esjzN4mr #Biocartis #Idylla #PrecisionMedicine #MolecularDiagnostics #Oncology *For Research Use Only (RUO), not for use in diagnostic procedures.